What are Wegovy tablets?
Wegovy tablets are a once-daily oral form of semaglutide used for weight loss and weight management in suitable adults. They are intended to be used alongside a reduced-calorie diet and increased physical activity.
Semaglutide is a GLP-1 receptor agonist. In simple terms, it works on appetite regulation, helping some people feel fuller, feel less hungry and reduce food cravings. Wegovy injections and Wegovy tablets contain the same active drug, but the tablet is absorbed through the stomach rather than injected under the skin.
Important: Wegovy, Mounjaro and other GLP-1 medicines are prescription-only medicines. They should only be used after a proper clinical assessment and should not be bought from unregistered websites or social media sellers.
How Wegovy tablets are taken
The daily tablet routine is very different from a weekly injection. For the tablet to work properly, it needs to be taken in a consistent way.
- Take the tablet after fasting, usually first thing in the morning.
- Swallow it whole with a small sip of water.
- Wait at least 30 minutes before eating, drinking or taking other medicines.
- Take it daily, rather than once weekly.
Eating, drinking or taking other medicines too soon after the tablet can reduce how much semaglutide is absorbed.
Why might someone switch from an injection to a tablet?
There are several reasons a patient may ask about switching to Wegovy tablets. Some people dislike needles, some find weekly injection days difficult to remember, and others may prefer a medicine that does not involve storing or carrying injection pens.
A tablet may suit you if...
- You struggle with needles or injection anxiety.
- You prefer a daily routine.
- You can reliably take medicine before breakfast.
- You want to discuss a semaglutide option with no injection device.
An injection may still suit you if...
- Your current injection is working well and you tolerate it.
- You find daily medicines hard to remember.
- You take other essential medicines first thing in the morning.
- You get nausea when taking tablets on an empty stomach.
What are the key principles of switching GLP-1 medicines?
A safe switch depends on more than the name of the injection. Your prescriber will look at your current medicine, your dose, how long you have been on that dose, side effects, other medicines, diabetes status, your weight loss progress and the timing of your last injection.
Half-life is one useful guide. This means the time it takes your body to clear around half of a dose. Some GLP-1 medicines remain in the body for weeks, but a prescriber may still advise switching before the medicine has completely cleared if that is the safest and most practical plan for you.
| Medicine you are switching from | Approximate half-life | What this means in practice | Usual timing before starting Wegovy tablets |
|---|---|---|---|
| Saxenda or Nevolat liraglutide |
About 13 hours | Liraglutide is a daily injection and leaves the body more quickly than weekly GLP-1 injections. | A short gap may be enough. Your prescriber may advise starting when the next daily dose would have been due, or within a few days. |
| Wegovy injection semaglutide |
About 1 week | Semaglutide can remain in the circulation for several weeks, but the injection and tablet contain the same active ingredient. | Usually one week after your last injection, on the day your next injection would have been due. The clearest licensed switch is from Wegovy 2.4mg weekly to Wegovy 25mg tablets daily. |
| Mounjaro tirzepatide |
About 5 days | Mounjaro is a weekly injection but contains tirzepatide, which is different from semaglutide. | Often around 7 days after your last injection, but your starting tablet strength should be chosen by a prescriber. |
This timing table is an educational guide only. It is not a washout rule and it is not a personal instruction to stop or start treatment.
Prescriber decision: your prescriber may start you lower than the tables below if you had nausea, vomiting, diarrhoea, constipation, reflux, a recent dose increase, a treatment break, diabetes, kidney concerns, gallbladder symptoms, pancreatitis history, or if you take medicines where timing or low blood sugar risk matters.
Wegovy tablet dose and switching tables
The following tables show the type of dose-matching discussion a prescriber may use. They are not guaranteed conversions. The only straightforward licensed switch is from Wegovy 2.4mg weekly injection to Wegovy 25mg tablets once daily, started one week after the last injection. For lower Wegovy doses and for Mounjaro, the final decision depends on the individual patient.
Wegovy tablet dose schedule
| Stage | Usual Wegovy tablet dose | Typical minimum time before increasing | Purpose |
|---|---|---|---|
| Start | 1.5mg once daily | Days 1 to 30 | Introduces treatment and helps reduce side effects. |
| Step 2 | 4mg once daily | Days 31 to 60 | Gradual dose increase if tolerated. |
| Step 3 | 9mg once daily | Days 61 to 90 | Further dose increase if clinically suitable. |
| Maintenance | 25mg once daily | Day 91 onwards | Maintenance dose for patients who tolerate treatment. |
Dose increases can be delayed if side effects occur. Do not take more than one Wegovy tablet per day.
Switching from Wegovy injection to Wegovy tablets
Wegovy injections and Wegovy tablets both contain semaglutide, so this is usually the most straightforward type of switch. The tablet dose is not milligram-for-milligram the same as the injection because the body absorbs tablets and injections differently.
| Current Wegovy injection dose | Wegovy tablet strength that may be considered | What your prescriber will consider |
|---|---|---|
| Wegovy 0.25mg weekly | 1.5mg or 4mg once daily may be considered. | Whether you have only just started treatment, whether you tolerated the first injection doses, and whether it is safer to follow tablet titration from the beginning. |
| Wegovy 0.5mg weekly | 4mg once daily may be considered, or 1.5mg if a cautious restart is safer. | Side effects, missed doses, your response so far and how long you have been stable on the injection. |
| Wegovy 1mg weekly | 4mg or 9mg once daily may be considered. | Whether you tolerated 1mg well, whether appetite control was adequate, and whether jumping to 9mg is appropriate for you. |
| Wegovy 1.7mg weekly | 9mg once daily may be considered, although some patients may need a lower tablet dose first. | Whether 1.7mg caused nausea, vomiting, diarrhoea, constipation or reflux, and whether your prescriber wants a more gradual change. |
| Wegovy 2.4mg weekly | 25mg once daily may be suitable, started one week after the last 2.4mg injection. | This is the clearest licensed switch. Your prescriber still needs to check tolerability, treatment response and medical history. |
The lower-dose rows are a clinical discussion guide, not a licensed equivalence table. Your prescriber may choose a different starting tablet strength.
Switching from Mounjaro to Wegovy tablets
Yes, switching from Mounjaro to Wegovy tablets can be possible. Mounjaro contains tirzepatide, while Wegovy tablets contain semaglutide. They are different medicines, so the table below should be treated as an example of how a prescriber may think about the switch, not as a direct conversion chart.
A prescriber may also recommend staying on Mounjaro if it is working well, moving to a lower Wegovy tablet dose if side effects have been an issue, or choosing a different route entirely if your medical history makes a switch unsuitable.
| Current Mounjaro dose | Wegovy tablet strength that may be considered | Why the final plan may be different |
|---|---|---|
| Mounjaro 2.5mg weekly | 1.5mg or 4mg once daily may be considered. | If you are early in treatment, have had side effects, or have had a treatment gap, your prescriber may start cautiously. |
| Mounjaro 5mg weekly | 4mg or 9mg once daily may be considered. | Depends on how long you have been on 5mg, how well it controlled appetite, and how well you tolerated it. |
| Mounjaro 7.5mg weekly | 9mg once daily may be considered. | Some prescribers may still choose 4mg first if you had gastrointestinal side effects or a recent dose increase. |
| Mounjaro 10mg weekly | 9mg once daily may be considered; 25mg may be considered in selected stable patients. | Your previous weight loss, appetite control, side effects and risk factors matter more than the dose number alone. |
| Mounjaro 12.5mg weekly | 9mg or 25mg once daily may be considered. | Your prescriber may avoid 25mg if you recently increased dose, had nausea, or would be safer with a staged tablet titration. |
| Mounjaro 15mg weekly | 25mg once daily may be considered, but is not automatic. | Even at the highest Mounjaro dose, a prescriber may choose 9mg first if a cautious transition is safer. |
Mounjaro and Wegovy are not interchangeable dose-for-dose. The table helps patients understand what may be discussed, but the prescriber can choose a lower or different plan depending on the person.
Why these tables need a caveat
Two people on the same injection strength may not need the same tablet strength. A patient who has tolerated treatment for months may be treated differently from someone who has only just increased dose or has ongoing side effects. This is why a conversion table can be helpful for understanding the conversation, but it should never replace a clinical decision.
What side effects should you consider?
The most common side effects with Wegovy tablets are stomach and bowel side effects such as nausea, diarrhoea, constipation, abdominal pain, indigestion and vomiting. These are often more noticeable when starting treatment or increasing dose.
Tell your prescriber about any previous side effects from Wegovy, Mounjaro, Saxenda, Ozempic or Rybelsus. This helps them choose a cautious plan and decide whether switching is sensible.
Questions to ask before switching
- Am I switching because my current treatment is not working, or because I prefer tablets?
- Can I take a tablet correctly every morning before food, drink or other medicines?
- Have I had side effects that might return when I change dose or medicine?
- Do I take diabetes medicines that could increase the risk of low blood sugar?
- Could I be pregnant, planning pregnancy or breastfeeding?
- What should I do if I miss a dose?
Need weight loss treatment support?
McKeevers Chemists can help you understand the correct route, whether you already have a private prescription or need to request a consultation.
Start with McKeevers weight loss serviceFrequently asked questions
Can I switch from Wegovy injections to Wegovy tablets?
It may be possible, especially if you are already stable on Wegovy 2.4mg weekly, but your prescriber must confirm the timing and dose. Do not overlap injection and tablet treatment unless specifically instructed.
Can I switch from Mounjaro to Wegovy tablets?
Yes, switching can be possible, but it is not a direct dose conversion. Mounjaro contains tirzepatide and Wegovy contains semaglutide, so your prescriber must choose the timing and starting tablet strength based on your clinical history, current dose and side effects.
Are Wegovy tablets better than injections?
Not necessarily. Tablets may be easier for people who dislike injections, but they require a strict daily fasting routine. The best option depends on your response, tolerance, medical history and routine.
Do Wegovy tablets need to be taken every day?
Yes. Wegovy tablets are taken once daily. Wegovy and Mounjaro injections are usually taken once weekly.
Can I buy Wegovy tablets without a prescription?
No. Wegovy tablets are prescription-only. You should only obtain them from a registered pharmacy after an appropriate assessment.
References
- MHRA: First GLP-1 tablet for weight loss approved in the UK
- European Medicines Agency: First oral GLP-1 treatment for weight management
- MHRA: GLP-1 medicines for weight loss and diabetes — patient information
- FDA prescribing information: Wegovy injection and Wegovy tablets
- EMA product information: Wegovy, semaglutide
- electronic Medicines Compendium: Mounjaro KwikPen SmPC
- electronic Medicines Compendium: Saxenda SmPC
- Wharton S, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine.
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine.